Evidence map›Paper›PMID 42650996›Full record

ArticleDiagnostics (Basel, Switzerland)2026

Monoclonal Antibody-Based ELISA Quantification of Serum Methylglyoxal-Derived Hydroimidazolone-1.

Jun Nojima, Masatsuna Tasaka, Hidetsugu Fujigaki, Sayaka Sugiura, Yasuko Yamamoto, Tetsuro Enomoto, Yushi Matuo, Kuniaki Saito

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun NojimaNagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd., Nagahama 174-8505, Japan.
Masatsuna TasakaDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.
Hidetsugu FujigakiDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.
Sayaka SugiuraDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.
Yasuko YamamotoDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.
Tetsuro EnomotoNagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd., Nagahama 174-8505, Japan.
Yushi MatuoDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.
Kuniaki SaitoDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake 470-1192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced glycation end products (AGEs)diabetic kidney diseaseenzyme-linked immunosorbent assay (ELISA)methylglyoxal-derived hydroimidazolone-1 (MG-H1)MG-H1 specific monoclonal antibody

Identifiers

PMID42650996
PMCPMC13512253

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.